Delfi Diagnostics

Delfi Diagnostics

Private
Baltimore, MarylandHealthcare & Life Scienceshttps://www.delfidiagnostics.com

Last Round

Series B

Jul 18, 2022

Total Funding Raised

$330.5M

Company Overview

Delfi Diagnostics is a healthcare technology company that specializes in a blood test system for the early detection of cancer using machine learning to identify cancer-associated cell-free DNA fragments for timely and effective treatment.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

liquid biopsyearly cancer detectioncancer blood testfragmentomicsmachine learning diagnosticscell-free DNAcfDNAlung cancer screeningwhole-genome sequencingtreatment monitoringcancer diagnosticslaboratory-developed testLDTprecision oncologyoncology drug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Delfi Diagnostics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Delfi Diagnostics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series BJul 18, 2022
Series AJan 12, 2021
SeedAug 27, 2019

Key People

Founding team and executive leadership

Susan Tousi

CEO

Executive Team

Delfi Diagnostics Investors

Notable investors and investment history

InvestorRounds
PTX CapitalSeries B
Brown AdvisorySeries B
Bollinger Investment GroupSeries A
TD SecuritiesSeries B, Series A
Osage University PartnersSeries B
OrbiMedSeries B, Series A
Open Field CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 17, 2026

    Five poster presentations at AACR 2026 Annual Meeting.

  • Apr 6, 2026

    Showcasing advances to whole-genome cfDNA platform at AACR 2026.

Delfi Diagnostics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Delfi Diagnostics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Delfi Diagnostics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBaltimore, Maryland
Employee Range165
Year Founded2019
Last FundingJul 18, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.